Deliver Your News to the World

Second Time’s a Charm for Somaxon (NASDAQ:SOMX)


StocksHaven Investments

StocksHaven Investments news portal takes a closer look at Somaxon Pharmaceuticals, Inc. (NASDAQ:SOMX), which hopes its drug, Silenor will be approved for the treatment of insomnia.

StocksHaven Investments profiles one of the most promising biomedical pharmaceutical company involved with a PDUFA with regards to a drug which could quite possibly revolutionize the treatment for insomnia, a condition affecting over 70 million Americans. The company has been making waves the past few months as investors and institutions gain confidence from the highly positive clinical trials, and the recent exclusive meeting with the FDA with regards to their NDA. Somaxon Pharmaceuticals is a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary products and late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area. The lead product candidate is Silenor® (doxepin) for the treatment of insomnia. The FDA decision date on Silenor has been set to 12/4/09 for their NDA resubmission, the importance of this is discussed further in the article.

The full special report on the company appears today at

Disclosure: Long-Term Position


About StocksHaven Investments

StocksHaven Investments can be found at It is a company offering a news portal covering the world financial news and equities sector. It features its own blog, free level 2 quotes, two way linking capability, investment dictionary, stock research reports, conference calls, news feeds, mailing list, videos, press release capability, stock commentaries, company reviews and other unique content including expert stock analysis from Michael Vlaicu. The company also offers PR relations and contracting services.

For more financial and investment news, visit

Certain sections of this report contain forward-looking statements that are based on our reporters’ expectations, estimates, projections and assumptions. Words such as “expects,” “anticipates,” “plans,” “believes,” “scheduled,” “estimates” and variations of these words and similar expressions are intended to identify forward-looking statements, which include but are not limited to projections of revenues, earnings, segment performance, cash flows, contract awards, FDA announcements, trial and drug approvals, and company stability. Forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. These statements are not guarantees of future performance and involve certain risks and uncertainties, which are difficult to predict. Therefore, actual future results and trends may differ materially from what is forecast in forward-looking statements due to a variety of factors including but not limited to the status or outcome of legal and/or regulatory proceedings.

All forward-looking statements speak only as of the date of this report or, in the case of any document incorporated by reference, the date of that document. All subsequent written and oral forward-looking statements attributable to the company or any person acting on the company’s behalf are qualified by the cautionary statements in this section. StocksHaven.Com does not undertake any obligation to update or publicly release any revisions to forward-looking statements to reflect events, circumstances or changes in expectations after the date of this report.


 somaxon pharmaceuticals
 nasdaq somx
 somaxon silenor pdufa
 fda silenor insomnia
 silenor insomnia product

This news content may be integrated into any legitimate news gathering and publishing effort. Linking is permitted.

News Release Distribution and Press Release Distribution Services Provided by WebWire.